Related Experiment Video
Updated: Nov 4, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Cardiotoxicity in yew berry poisoning
Mohammad Alarfaj1, Ankur Goswami2
1Department of Medicine, McMaster University, Canada.
Yew plant (Taxus species) poisoning can cause fatal cardiac arrhythmias. Current management strategies are varied, highlighting the need for improved understanding and treatment guidelines for this rare toxidrome.
Area of Science:
- Toxicology
- Cardiology
- Plant Science
Background:
- Yew plants (Taxus species) are known for their toxicity, primarily due to cardiotoxic effects causing fatal arrhythmias.
- Lethal intoxication from yew poisoning is rare, but management guidelines are lacking, leading to varied treatment approaches.
Observation:
- A case of a 20-year-old female with refractory lethal arrhythmia and shock following yew poisoning is presented.
- The patient required intensive care, including airway management, hemodynamic support, antiarrhythmics, digoxin immune Fab, lipid emulsion, and pacemaker insertion.
Findings:
- Despite extensive interventions, the patient ultimately died, and care was withdrawn.
- A review of 43 literature cases identified common treatments such as gastric decontamination, antiarrhythmics, pacing, and extracorporeal life support.
Implications:
- There is a critical need for a better understanding of yew plant poisoning management.
- Identifying optimal therapies is essential to improve outcomes for this rare but severe toxidrome.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Prevention of Further Absorption of Poison
Cardiopulmonary Resuscitation IV: Pharmacological Management
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

